Page 35 - MRS Abstracts March 2023
P. 35
Do Janus Kinase Inhibitors lead to weight gain in Rheumatoid Arthritis Patients
Nadeem Mir1
Naina Naina1
Hafis Muhammed1 George Hirsch1
Tom Sheeran1 Srinivasan Venkatachalam1
1Rheumatology Department, The Royal Wolverhampton NHS Trust Introduction:
Janus kinase (JAK) inhibitors are promising drugs in the treatment of various autoimmune rheumatic disorders. While the clinical efficacy of JAK inhibitors is well-documented, an intriguing and clinically significant aspect the potential association between JAK inhibitors and weight gain is being reported.
We aimed to investigate the changes in weight in rheumatoid arthritis (RA) patients treated with JAK inhibitors and the factors associated with it.
Methods:
We conducted a retrospective analysis of RA patients initiated on JAK inhibitors between January 2018 and December 2022 in a regional rheumatology unit in the United Kingdom. Demographic information, disease activity measures, concurrent DMARDs, steroid use, and comorbidities were collected besides the weight recorded at each clinic visit for up to 24 months.
Percentage change in weight at 9-12 months was calculated for each group. Linear mixed-effects models were developed for change in weight gain considering various factors which could be implicated. To visualize the weight trajectory, LOESS (Locally Weighted Scatterplot Smoothing) plots
